Screener
Kiniksa Pharmaceuticals International, plc KNSA Deferred Tax Assets
Deferred Tax Assets at other companies
Segments
By geography
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxAssetsNet.
The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-087545
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease right-of-use assets | 8,353 | 9,807 |
| Other long-term assets | 10,834 | 11,307 |
| Intangible asset, net | 14,750 | 15,250 |
| Deferred tax assets | 190,965 | 198,149 |
| Total assets | $896,110 | $763,633 |
| Liabilities and Shareholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $12,404 | $2,028 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kiniksa Pharmaceuticals International, plc's deferred tax assets?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported deferred tax assets of $190.97M in Q2 2026.
- How has Kiniksa Pharmaceuticals International, plc's deferred tax assets changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's deferred tax assets decreased by 7.1% year-over-year, from $205.51M to $190.97M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's deferred tax assets?
- Over 4 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's deferred tax assets has grown at a 1086.4% compound annual growth rate (CAGR), from $10K to $198.15M.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.
Ask your AI about Kiniksa Pharmaceuticals International, plc's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude